On behalf of the International Society of Paediatric Oncology (SIOP), please note that SIOP 2020 will take place as a virtual congress on the same dates: October 14-17, 2020. Additionally, Late-Breaking Abstract Submission is open until August 26, allowing everyone to share their research from wherever they are based. SIOP 2020 Virtual Congress October 14-17, 2020 www.siop-congress.org In light of the continuing uncertainty about the evolution of the COVID-19 pandemic, we have decided to transform SIOP 2020 into a virtual congress, taking place on the same dates: October 14-17, 2020. With updated registration rates starting from EUR 25, […]
Read moreCurrently browsing: Community News
Community News: Update on Federal Childhood Cancer Appropriations Process
Update from our colleagues at the Alliance for Childhood Cancer (July 13, 2020): The House Appropriations Committee agreed to fully fund the Childhood Cancer STAR Act and the Childhood Cancer Data Initiative again this year. Notably, the Senate has historically championed our cause for STAR funding, so this development in the House shows an even stronger commitment from Congress for our research priorities. This step is important to our requests being included in the final appropriations package when Congress considers the next budget. Here are some key sections related to childhood cancer: STAR Act – The Committee includes no [...] Read more
FDA Approves Gemtuzumab Ozogamicin for CD33-Positive AML in Pediatric Patients
On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARGTM, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients 1 month and older. Read More Here On June 16, 2020, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA®, Merck & Co., Inc.) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. Read [...] Read more
AACR Sponsored Listening Session with FDA
The American Association for Cancer Research (AACR) and the U.S. Food and Drug Administration (FDA) recorded a listening session on May 27, 2020 for patient advocates to learn more about cancer clinical trials during COVID-19. The session is about 45 minutes, with the pediatric questions at about minute 25.5, minute 37, and minute 41. FDA Listening Session: Oncology and Covid-19
Read moreDay One Biopharmaceuticals
Day One Biopharmaceutical, a start-up biotech company founded with a focus on developing therapies for children with cancer through drug repurposing announced its debut in the market last week. Its first agent, DAY101, licensed from Takeda Pharmaceuticals, is a targeted treatment for children with low grade glioma, a type of brain cancer. DAY101 is a Phase 2-ready RAF inhibitor that also shows strong potential for other pediatric and adult indications. The company is co-founded by Chief Medical Officer Dr. Sam Blackman (who offered our May webinar) and Acting CEO Julie Grant from Canaan Partners. You can read more here. Please look for a […]
Read more
CAC2 Member Blog–Jointly Sponsored Moonshot4Kids Congressional Briefing
CAC2 Members Jack’s Angels, Dragon Master Foundation, Max Cure Foundation, Children’s Cancer Cause, and National Brain Tumor Society joined together with others in the community through the DIPG Advocacy Group to hold the Moonshot4Kids Congressional Briefing on February 13 to raise awareness of H. Res. 114, which “Expressing support for the designation of the 17th day in May as “DIPG Awareness Day” to raise awareness and encourage research into cures for diffuse intrinsic pontine glioma (DIPG) and pediatric cancers in general.” You can read more about the Briefing and H. Res. 114 at CAC2 Blog Post #Moonshot4Kids. According to CAC2 […]
Read more
CAC2 Special Community Webinar–Vincristine Drug Shortage Update
Dr. Peter Adamson, Chair of the Children's Oncology Group (COG), shared information that COG has received along with a perspective on childhood cancer drug shortages, including the current situation with vincristine. We were pleased to join with the Alliance for Childhood Cancer to invite members of the two coalitions and the wider community this Community webinar. We offered this webinar so that the community could have a better understanding of the shortage, how to work with care providers, how to contact the FDA when problems arise from the shortage, and advocacy steps being taken. PUT_CHARACTERS_HERE Read more
STAR Act Co-Sponsor Map
Thanks to the many-faceted efforts in the childhood cancer community, the STAR Act has reached a tipping point (173 co-sponsors in the House of Representatives as of March 3, 2016). This is an important milestone in moving the bill through the legislative process. In March the focus is to push for even more co-sponsors, with a strong emphasis on Members who serve on the Energy & Commerce Committee. We want as many Members as possible supporting the bill, so that we can move the bill to a successful committee hearing. This map will help you locate your Representative: Hovering over or clicking each marker will […]
Read morePediatric Cancer: Major Advances, Major Challenges – Notes from the 5th Annual Childhood Cancer Caucus
The Congressional Childhood Cancer Caucus Presents Pediatric Cancer: Major Advances, Major Challenges 5th Annual Childhood Cancer Caucus Friday, September 19, 2014 9:00 – 10:30 a.m. Congressional Auditorium, US Capitol Visitors Center Co-Chairs: Congressman Michael T. McCaul (R-TX) Congressman Chris Van Hollen (D-MD) Keynote speaker: Dr. Francis Collins, Director, National Institutes of Health (NIH) Speakers: Dr. Ronald DePinho, President, MD Anderson Cancer Center Dr. Amrit Ray, Chief Medical Officer, Johnson & Johnson – Janssen Pharmaceuticals Notes: by CAC2 Member Laurie Orloski Opening remarks Vickie Buenger, President of the Coalition of Childhood Cancer (CAC2) Vickie Buenger kicked off the Caucus by welcoming […]
Read moreNCI Meeting Scheduled for Fri. Feb 21
There will be a meeting next week at the National Cancer Institute (NCI) dedicated to pediatric cancer drug development. The National Cancer Institute (NCI) will hold its 64th Meeting of the Director’s Consumer Liaison Group (DCLG) on Friday, February 21, 2014 from 9:30 a.m. to 4:00 p.m. on the National Institutes of Health (NIH) Campus in Bethesda, MD. The meeting will focus on barriers to drug development in pediatric cancer research and will include participants from the pediatric cancer advocacy community, as well as private and public sector presenters. The panels will discuss the State of Pediatric Cancer Research, Potential […]
Read more